This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Impax Laboratories, Inc.
Drug Names(s): URSO 250
Description: Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of ursodiol increases this fraction in a dose related manner, to become the major biliary acid, replacing/displacing toxic concentrations of endogenous hydrophobic bile acids that tend to accumulate in cholestatic liver disease. In addition to the replacement and displacement of toxic bile acids, other mechanisms of action include cytoprotection of the injured bile duct epithelial cells (cholangiocytes) against toxic effects of bile acids, inhibition of apotosis of hepatocytes, immunomodulatory effects, and stimulation of bile secretion by hepatocytes and cholangiocytes
Aptalis and Forest
In January 2014, Aptalis announced that it has signed a definitive agreement to be acquired by Forest Laboratories. Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash, pending required reviews by anti-trust authorities in the US and Canada. Forest expects to use a combination of cash on hand and debt to fund the transaction.
In February 2014, Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will now begin combined operations, with Aptalis operating as a subsidiary of Forest Laboratories.
In July 2014, Actavis announced that it has completed the acquisition of Forest in a cash and equity transaction currently valued at approximately $28 billion.
Impax and Actavis
In July 2014, Impax Laboratories announced that it has acquired from Actavis, two...See full deal structure in Biomedtracker
URSO Forte News
Pink Sheet September 2004 Supplements
Additional information available to subscribers only: